Cargando…

Whole-exome sequencing of long-term, never relapse exceptional responders of trastuzumab-treated HER2+ metastatic breast cancer

Trastuzumab has significantly improved the overall survival of patients with HER2+ metastatic breast cancer (MBC). However, outcomes can vary, with patients progressing within 1 year of treatment or exceptional cases of complete response to trastuzumab for ≥10 years. Identification of the underlying...

Descripción completa

Detalles Bibliográficos
Autores principales:	Walsh, Naomi, Andrieu, Charlotte, O’Donovan, Peter, Quinn, Cecily, Maguire, Alanna, Furney, Simon J., Gullo, Giuseppe, Crown, John
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2020
Materias:	Brief Communication
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7553955/ https://www.ncbi.nlm.nih.gov/pubmed/32713940 http://dx.doi.org/10.1038/s41416-020-0999-z

Ejemplares similares

Impact of timing of trastuzumab initiation on long-term outcome of patients with early-stage HER2-positive breast cancer: the “one thousand HER2 patients” project
por: Gullo, Giuseppe, et al.
Publicado: (2018)

Neratinib overcomes trastuzumab resistance in HER2 amplified breast cancer
por: Canonici, Alexandra, et al.
Publicado: (2013)

Germline single nucleotide polymorphisms in ERBB3 and BARD1 genes result in a worse relapse free survival response for HER2-positive breast cancer patients treated with adjuvant based docetaxel, carboplatin and trastuzumab (TCH)
por: Coté, Damien, et al.
Publicado: (2018)

Phase Ib Trial of Copanlisib, A Phosphoinositide-3 Kinase (PI3K) Inhibitor, with Trastuzumab in Advanced Pre-Treated HER2-Positive Breast Cancer “PantHER”
por: Keegan, Niamh M., et al.
Publicado: (2021)

Exceptional Responder to Immunotherapy: A Rare Case of Post-HSCT DLBCL Relapse Responding to Nivolumab
por: Madabhavi, Irappa, et al.
Publicado: (2019)

The impact of ERBB-family germline single nucleotide polymorphisms on survival response to adjuvant trastuzumab treatment in HER2-positive breast cancer
por: Toomey, Sinead, et al.
Publicado: (2016)

Clinical Impact of Immune Checkpoint Inhibitor (ICI) Response, DNA Damage Repair (DDR) Gene Mutations and Immune-Cell Infiltration in Metastatic Melanoma Subtypes
por: Andrieu, Charlotte, et al.
Publicado: (2022)

It’s never endometriosis, except when it’s endometriosis
por: Libretti, Alessandro, et al.
Publicado: (2023)

Alterations in integrin expression modulates invasion of pancreatic cancer cells
por: Walsh, Naomi, et al.
Publicado: (2009)

Trastuzumab treatment after progression in HER2-positive metastatic breast cancer following relapse of trastuzumab-based regimens: a meta-analysis
por: Han, Yiqun, et al.
Publicado: (2019)

Her Health, Common Dangers and Salvation
por: O'Donovan, W. J.
Publicado: (1918)

Exome sequencing of three cases of familial exceptional longevity
por: Cash, Timothy P, et al.
Publicado: (2014)

Generation of HER2-specific antibody immunity during trastuzumab adjuvant therapy associates with reduced relapse in resected HER2 breast cancer
por: Norton, Nadine, et al.
Publicado: (2018)

Long-term responders to trastuzumab monotherapy in first-line HER-2+ advanced breast cancer: characteristics and survival data
por: Schmid, Sabine, et al.
Publicado: (2019)

Effect of Trastuzumab–HER2 Complex Formation on Stress-Induced Modifications in the CDRs of Trastuzumab
por: Spanov, Baubek, et al.
Publicado: (2022)

Predictive modelling of response to neoadjuvant therapy in HER2+ breast cancer
por: Cosgrove, Nicola, et al.
Publicado: (2023)

Metastatic HER2+ Breast Cancer: A Potentially Curable Disease?
por: Prior, Lisa, et al.
Publicado: (2017)

Comparative molecular characterization of typical and exceptional responders in glioblastoma
por: Wipfler, Kristin, et al.
Publicado: (2018)

Targeted treatment of advanced and metastaticbreast cancer with lapatinib
por: Corkery, Brendan, et al.
Publicado: (2008)

The role of infiltrating lymphocytes in the neo-adjuvant treatment of women with HER2-positive breast cancer
por: Eustace, A. J., et al.
Publicado: (2021)

HER2 therapy: Molecular mechanisms of trastuzumab resistance
por: Nahta, Rita, et al.
Publicado: (2006)

Targeting HER2 in breast cancer: beyond trastuzumab
por: Winer, EP
Publicado: (2011)

Quantification of Trastuzumab–HER2 Engagement In Vitro and In Vivo
por: Rudkouskaya, Alena, et al.
Publicado: (2020)

Whole exome sequencing to identify genetic markers for trastuzumab‐induced cardiotoxicity
por: Udagawa, Chihiro, et al.
Publicado: (2018)

ADAM10 and ADAM17: New Players in Trastuzumab Resistance
por: Duffy, Michael J., et al.
Publicado: (2014)

Pro1170 Ala polymorphism in HER2-neu is associated with risk of trastuzumab cardiotoxicity
por: Stanton, Sasha E, et al.
Publicado: (2015)

Cost-effectiveness analysis of trastuzumab deruxtecan versus trastuzumab emtansine for HER2-positive breast cancer
por: Yang, Jiangping, et al.
Publicado: (2022)

Mode of action and pharmacogenomic biomarkers for exceptional responders to didemnin B
por: Potts, Malia B., et al.
Publicado: (2015)

Characteristics of exceptional responders to lenalidomide-based therapy in multiple myeloma
por: Vu, T, et al.
Publicado: (2015)

An exceptional response to nivolumab in relapsed and refractory malignant mesothelioma
por: Talreja, Vikas T., et al.
Publicado: (2019)

HER2-Targeted Tyrosine Kinase Inhibitors Cause Therapy-Induced-Senescence in Breast Cancer Cells
por: McDermott, Martina S. J., et al.
Publicado: (2019)

Whole Exome Sequencing of Thymoma Patients Exhibiting Exceptional Responses to Pemetrexed Monotherapy
por: Tanaka, Tomohiro, et al.
Publicado: (2023)

Cardiotoxicity of trastuzumab in patients with HER2-positive gastric cancer
por: Soo Park, Ji, et al.
Publicado: (2017)

Cryo-EM Structure of HER2-trastuzumab-pertuzumab complex
por: Hao, Yue, et al.
Publicado: (2019)

PP2A inhibition overcomes acquired resistance to HER2 targeted therapy
por: McDermott, Martina SJ, et al.
Publicado: (2014)

Addition of GM-CSF to trastuzumab stabilises disease in trastuzumab-resistant HER2+ metastatic breast cancer patients
por: Cheng, Y C, et al.
Publicado: (2010)

Neoadjuvant PF-05280014 (a potential trastuzumab biosimilar) versus trastuzumab for operable HER2+ breast cancer
por: Lammers, Philip E., et al.
Publicado: (2018)

Neratinib plus trastuzumab is superior to pertuzumab plus trastuzumab in HER2-positive breast cancer xenograft models
por: Veeraraghavan, Jamunarani, et al.
Publicado: (2021)

Termination of trastuzumab in HER2-positive metastatic breast cancer patients who received trastuzumab beyond progression
por: Dogan, Izzet, et al.
Publicado: (2023)

HER2-positive metastatic breast cancer with brain metastases responds favorably to pyrotinib and trastuzumab-based treatment: A case report and literature review
por: Chen, Min-long, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_lcmivpqqpfbnmneoj585bh83dj